Stocks Health care IRD
NASDAQ · Health careOpus Genetics, Inc. (IRD)
Opus Genetics, Inc. brought in $9.9M of revenue over the twelve months to June 30, 2026, down 36.1% from a year earlier. It posted a net loss of $107.6M. At June 30, 2026 it held $88.8M in cash against $35.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Opus Genetics, Inc. does
Opus Genetics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IRD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.2M | -$49.6M | -$0.80 | n/a |
| 2024 | $11M | -$57.5M | -$2.15 | n/a |
| 2023 | $19M | -$10M | -$0.46 | n/a |
| 2022 | $39.9M | $17.9M | $0.87 | n/a |
| 2021 | $589K | -$56.7M | -$3.82 | n/a |
| 2020 | $0 | -$24.6M | -$5.28 | -$6.8M |
Latest SEC filings
What Opus Genetics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026
- September 9, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 17, 2026
- June 16, 2026
Questions about IRD
What does Opus Genetics, Inc. do?
Opus Genetics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IRD.
Is Opus Genetics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $107.6M on revenue of $9.9M.
How much revenue does Opus Genetics, Inc. make?
Over the twelve months to June 30, 2026 Opus Genetics, Inc. reported revenue of $9.9M. That is 36.1% less than a year earlier.
When did Opus Genetics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 11, 2026.
Similar companies
Follow IRD
Get an email when Opus Genetics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow IRD: get an email when it filesWhere the numbers come from
Financial figures are the values Opus Genetics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.